BBH - VanEck Vectors Biotech ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
121.29
-1.35 (-1.10%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close122.64
Open122.61
Bid115.06 x 1400
Ask136.66 x 800
Day's Range120.96 - 122.61
52 Week Range103.25 - 136.84
Volume13,542
Avg. Volume14,846
Net Assets410.66M
NAV122.69
PE Ratio (TTM)N/A
Yield0.43%
YTD Return10.20%
Beta (3Y Monthly)1.52
Expense Ratio (net)0.35%
Inception Date2011-12-20
Trade prices are not sourced from all markets
  • Will Biotech ETFs Continue to Rally in Q1 Earnings?
    Zacks7 hours ago

    Will Biotech ETFs Continue to Rally in Q1 Earnings?

    Here we study the possible impact of some major Q1 earnings releases on certain biotech ETFs .

  • Health Day Checkup of Medical ETFs: 5 Top Picks
    Zacks20 days ago

    Health Day Checkup of Medical ETFs: 5 Top Picks

    M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

  • Top-Ranked ETF Winners in Dow's Longest Rally in 24 Years
    Zacks2 months ago

    Top-Ranked ETF Winners in Dow's Longest Rally in 24 Years

    While there are winners in many corners of the space, some ETFs have crushed the Dow Jones by wide margins in three months.

  • Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
    Zacks2 months ago

    Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

    Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

  • What's Behind the Biotech ETF Rally to Start 2019?
    Zacks3 months ago

    What's Behind the Biotech ETF Rally to Start 2019?

    Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.

  • Biotech ETFS: How To Pick Biotech Stock Winners And Avoid Volatility In 2019
    Investor's Business Daily3 months ago

    Biotech ETFS: How To Pick Biotech Stock Winners And Avoid Volatility In 2019

    Biotech ETFs allow investors to buy into a basket of biotech stocks, rather than trying to select specific winners. The best biotech ETFs are diverse, with less volatility.

  • Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus
    Zacks4 months ago

    Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus

    The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.

  • Business Wire5 months ago

    VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors Equity ETFs

    VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® equity exchange-traded funds.

  • Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings
    Market Realist6 months ago

    Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings

    Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion, compared to estimates for EPS of $4.03 on revenues of $3.88 billion during the third quarter of 2018.

  • Recommendations for Shire as of October 30
    Market Realist6 months ago

    Recommendations for Shire as of October 30

    There are 11 analysts tracking Shire stock as of October 30. Four of them are recommending a “strong buy,” five are recommending a “buy,” and two are recommending a “hold.” None of them have recommended a “sell.” The changes in analysts’ estimates and recommendations are based on changing trends in the stock and the company’s performance.

  • What Analysts Recommend for Incyte ahead of Q3 Earnings
    Market Realist6 months ago

    What Analysts Recommend for Incyte ahead of Q3 Earnings

    Wall Street analysts estimate Incyte’s (INCY) revenues will increase by ~17.7% to $449.2 million during the third quarter of 2018 compared to revenues of $381.5 million during the third quarter of 2017. Also, the earnings per share are estimated to be $0.40 for the third quarter of 2018 as compared to earnings per share of $0.08 for the third quarter of 2017. Incyte stock has fallen nearly 46.6% over the last 12 months and decreased by ~35.7% in 2018 year-to-date.

  • Amgen: Expect Nearly Flat Revenues in Q3
    Market Realist6 months ago

    Amgen: Expect Nearly Flat Revenues in Q3

    As we discussed earlier, analysts expect Amgen (AMGN) to report nearly flat revenues at $5.77 billion during the third quarter. Amgen’s product portfolio includes human therapeutics.

  • Allergan’s Q3 2018 Estimates: Revenue Decline Expected
    Market Realist6 months ago

    Allergan’s Q3 2018 Estimates: Revenue Decline Expected

    Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decrease 3.8% to $3.88 billion. Allergan has classified its business operations into three business segments: US Specialized Therapeutics US General Medicine International

  • Biogen: Analysts’ Recommendations on October 19
    Market Realist6 months ago

    Biogen: Analysts’ Recommendations on October 19

    Wall Street analysts expect Biogen’s (BIIB) third-quarter revenues to increase ~8.2% to $3.33 billion—compared to its revenues of $3.07 million during the third quarter of 2017. Biogen’s stock price has decreased nearly 4.1% in the last 12 months. Analysts’ recommendations show a 12-month target price of $390.88 per share—compared to the last price of $330.15 per share as of October 18.

  • Business Wire6 months ago

    VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry

    ESPO provides targeted exposure to “the future of sports”: video game and related software developers, streaming services, companies involved in eSports events, and more

  • Analysts Are Mostly Positive on Neurocrine Biosciences
    Market Realist7 months ago

    Analysts Are Mostly Positive on Neurocrine Biosciences

    Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.

  • Allergan’s Stock Performance and Estimates for Q3 2018
    Market Realist7 months ago

    Allergan’s Stock Performance and Estimates for Q3 2018

    Allergan’s (AGN) product portfolio includes generic pharmaceutical products and specialty pharmaceutical products. The company’s business comprises three segments—US General Medicines, US Specialized Therapeutics, and International. The chart below compares Allergan’s revenues and EPS since the first quarter of 2017, as well as its estimates for the third quarter.

  • Ionis Pharmaceuticals’ Valuations on September 28
    Market Realist7 months ago

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.

  • Allergan’s Developments in September
    Market Realist7 months ago

    Allergan’s Developments in September

    Allergan (AGN) is a specialty pharmaceutical company focused on organic as well as inorganic growth methods. The chart below highlights several recent developments for Allergan.

  • Estimates and Recommendations for Shire on September 19
    Market Realist7 months ago

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017. Analysts expect Shire’s net adjusted income to increase to $4.68 billion in 2018 compared to its net adjusted income of $4.60 billion in 2017. Shire’s stock price has risen nearly 15.4% in the last 12 months, and it’s risen ~15.7% year-to-date in 2018.

  • Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
    Market Realist8 months ago

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.

  • A Look at Incyte’s Valuation on August 22
    Market Realist8 months ago

    A Look at Incyte’s Valuation on August 22

    Incyte (INCY), a biopharmaceutical company, is focused on the discovery, development, and commercialization of various products to cater to unmet medical needs in oncology and the treatment of other diseases.

  • Examining Amgen’s Revenue Trend in Q2 2018
    Market Realist8 months ago

    Examining Amgen’s Revenue Trend in Q2 2018

    As we discussed earlier, Amgen (AMGN) reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017. Amgen surpassed analysts’ estimates for EPS and revenue in the second quarter, reporting non-GAAP (generally accepted accounting principles) EPS of $3.83 on revenue of ~$6.1 billion compared to the estimate of $3.54 on revenue of $5.7 billion.

  • Considering Allergan’s Q2 2018 Revenue Trend
    Market Realist8 months ago

    Considering Allergan’s Q2 2018 Revenue Trend

    As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.

  • What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
    Market Realist9 months ago

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.